Abstract
US Patent and Trademark Office data show a slowing of NIH-supported cancer patent innovation since 1995, amid criticism of an incremental rather than a high-risk, high-reward funding strategy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
